Beate Gruener

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/798950/publications.pdf

Version: 2024-02-01

32 papers	1,563 citations	471061 17 h-index	433756 31 g-index
32 all docs	32 docs citations	32 times ranked	1861 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nature Metabolism, 2021, 3, 149-165.	5.1	378
2	WHO classification of alveolar echinococcosis: Principles and application. Parasitology International, 2006, 55, S283-S287.	0.6	249
3	International consensus on terminology to be used in the field of echinococcoses. Parasite, 2020, 27, 41.	0.8	152
4	Worldwide literature on epidemiology of human alveolar echinococcosis: a systematic review of research published in the twenty-first century. Infection, 2019, 47, 703-727.	2.3	80
5	Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcosis multilocularis Ulm classification-ultrasound. World Journal of Gastroenterology, 2015, 21, 12392.	1.4	74
6	Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	3.9	72
7	Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World Journal of Gastroenterology, 2016, 22, 3621.	1.4	62
8	Close Relationship between Clinical Regression and Specific Serology in the Follow-up of Patients with Alveolar Echinococcosis in Different Clinical Stages. American Journal of Tropical Medicine and Hygiene, 2009, 80, 792-797.	0.6	61
9	Sensitive and Specific Immunohistochemical Diagnosis of Human Alveolar Echinococcosis with the Monoclonal Antibody Em2G11. PLoS Neglected Tropical Diseases, 2012, 6, e1877.	1.3	58
10	Immunoglobulin G Subclass Responses to Recombinant Em18 in the Follow-Up of Patients with Alveolar Echinococcosis in Different Clinical Stages. Vaccine Journal, 2010, 17, 944-948.	3.2	33
11	Alveolar echinococcosis in Germany, 1992â€“2016. An update based on the newly established national AE database. Infection, 2018, 46, 197-206.	2.3	32
12	Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany. GMS Infectious Diseases, 2017, 5, Doc01.	0.5	30
13	Echinococcus multilocularis: Inflammatory and regulatory chemokine responses in patients with progressive, stable and cured alveolar echinococcosis. Experimental Parasitology, 2008, 119, 467-474.	0.5	28
14	Close relationship between clinical regression and specific serology in the follow-up of patients with alveolar echinococcosis in different clinical stages. American Journal of Tropical Medicine and Hygiene, 2009, 80, 792-7.	0.6	28
15	Albendazole increases the inflammatory response and the amount of Em2-positive small particles of Echinococcus multilocularis (spems) in human hepatic alveolar echinococcosis lesions. PLoS Neglected Tropical Diseases, 2017, 11, e0005636.	1.3	25
16	Parasites of the liver â€“ epidemiology, diagnosis and clinical management in the European context. Journal of Hepatology, 2021, 75, 202-218.	1.8	24
17	Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease. Medical Microbiology and Immunology, 2014, 203, 185-193.	2.6	22
18	Surgery versus conservative drug therapy in alveolar echinococcosis patients in Germany â€“ A health-related quality of life comparison. Food and Waterborne Parasitology, 2019, 16, e00057.	1.1	15

#	Article	IF	Citations
19	A case for adoption of continuous albendazole treatment regimen for human echinococcal infections. PLoS Neglected Tropical Diseases, 2020, 14, e0008566.	1.3	15
20	Serological confirmatory testing of alveolar and cystic echinococcosis in clinical practice: results of a comparative study with commercialized and in-house assays. Clinical Laboratory, 2009, 55, 41-8.	0.2	15
21	Measurements of the trapezius and erector spinae muscles using virtual touch imaging quantification ultrasound-Elastography: a cross section study. BMC Musculoskeletal Disorders, 2017, 18, 370.	0.8	14
22	Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis. BMC Research Notes, 2018, 11, 101.	0.6	14
23	Simple liver cysts and cystoid lesions in hepatic alveolar echinococcosis: a retrospective cohort study with Hounsfield analysis. Parasite, 2019, 26, 54.	0.8	14
24	Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography. Scientific Reports, 2020, 10, 11808.	1.6	14
25	Emerging human alveolar echinococcosis in Hungary (2003â€“2018): a retrospective case series analysis from a multi-centre study. BMC Infectious Diseases, 2021, 21, 168.	1.3	14
26	Health-related quality of life in patients with alveolar echinococcosis: a cross-sectional study. Infection, 2019, 47, 67-75.	2.3	12
27	Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and Echinococcus-Specific IgG. Pathogens, 2022, 11, 239.	1.2	10
28	Combining Computed Tomography and Histology Leads to an Evolutionary Concept of Hepatic Alveolar Echinococcosis. Pathogens, 2020, 9, 634.	1.2	9
29	Salvage Therapy for Alveolar Echinococcosisâ€”A Case Series. Pathogens, 2022, 11, 333.	1.2	4
30	Echinococcus multilocularis specific antibody, systemic cytokine, and chemokine levels, as well as antigen-specific cellular responses in patients with progressive, stable, and cured alveolar echinococcosis: A 10-year follow-up. PLoS Neglected Tropical Diseases, 2022, 16, e0010099.	1.3	3
31	18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting. Pathogens, 2022, 11, 348.	1.2	1
32	Initial Risk Assessment in Patients with Alveolar Echinococcosisâ€”Results from a Retrospective Cohort Study. Pathogens, 2022, 11, 557.	1.2	1